Disease Pharmacology Injury in Acute Kidney

Acute Kidney Injury

The treatment of Acute Kidney Injury (AKI) has changed dramatically with the change in the management of comorbidities associated with it, such as hypertension. With this change, the rationale applied in the approach taken to treat these changes has also evolved. The use of pharmacologic treatment of AKI has been tried with varying success rates due to inefficiencies in implementing approaches used in trials with animals in humans or the effectiveness of some of the tries (1). Some of the experimental therapies used today are hypoperfusion, and the preventative intervention has been the intravenous administration of isotonic saline (3). The lack has informed intravascular volume expansion using isotonic saline of sufficient evidence that colloids are more effective for this purpose and evidence that some colloids may result in AKI. The high cost of colloids also limits their use.

Action Mechanisms of the Drugs Used for Treatment

In some patients, colloids are used to reach resuscitation or to avoid excessive administration of fluids or among cirrhotic patients who have spontaneous peritonitis. Hypertonic or hypnotic crystalloids may be applied in ideal clinical scenarios where the selected crystalloid with altered tonicity is dictated by other goals rather than intravascular volume expansion, such as hyponatremia or hypernatremia. Isotonic solutions have 154 mmol/l Chloride and, when administered in large amounts, may result in obsolete or relative hyperchloremia (6). The buffered saline solution approximates the concentration of physiological chloride and causes a decline in the acid-base distribution. Once the intravascular volume is optimized, it is uncertain which vasopressor agent is the most suitable for managing shock since there are negligible differences between renal mortality and function (4). However, Vasopressin is gaining preference compared to norepinephrine since it enhances diuresis and increases blood pressure but is yet proven to enhance survival.

Appropriate vasoactive agents can improve kidney perfusion among patients in volume-restricted who have a vasomotor shock. The lack of protocolized therapies and standardized care has an array that limits the efficacy of using postoperative therapies. Insufficient management strategies, standardized hemodynamic, and tissue oxygenation targets to assess the efficacy of the protocolized therapies compared to standard procedures have limited their adoption in practice despite proven incidences of benefit to some patients (1). Protocolized therapies aim to prevent AKI during the perioperative period informed by protocol, avoid hypotension, include careful fluid management, optimize oxygen delivery and vasopressors. Nootropic agents and blood products are also effective when needed. Protocols in treatment in the case of need for resuscitation in the event of septic shock or need for surgery are more effective than treatment without any protocols.

Side Effects of Drugs and their Contraindications

Loop diuretics, such as, have been prescribed for a long time in acute-care settings. Prophylactic Furosemide was harmful and ineffective when used to control or prevent AKI after cardiac surgery. Further, it increases AKI risk in cases when it was administered to prevent contrast-induced AKI. Loop diuretics have increased mortality among patients with AKI and a critical illness (3). However, Furosemide may be useful when used to achieve fluid balance and facilitate mechanical ventilation consistent with lung-protective ventilation strategy among patients who have a stable acute lung injury (2). The use of dopamine for AKI treatment is ineffective despite the increase in natriuresis. Although there has been evidence challenging the suitability of low dosages of dopamine among patients admitted in the ICU, it is still used extensively among critically ill patients.

Dopamine can trigger a decrease in intestinal blood flow, myocardial ischemia, and achyarrhythmias (3). It may also suppress the function of T-cell and hypopituitarism function. Fenoldopam mesylate is a Type 1 pure dopamine receptor agonist whose effect is similar to hemodynamic renal effects (1). In the absence of ?-adrenergic or ?-adrenergic stimulation. Mannitol is added to the priming fluid in the cardiopulmonary bypass system to reduce the incidence of renal dysfunction. However, the is a negligible function of this approach when applied to patients who initially had normal renal functioning and those who had renal dysfunction. However, the administration of 250 ml of 20% mannitol before the vessel cramp during renal transplant served a preventative function (6). Further, it reduced post-transplant incidences of AKI.